Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML)
T Lu, J Cao, F Zou, X Li, A Wang, W Wang… - European Journal of …, 2021 - Elsevier
As the critical driving force for chronic myeloid leukemia (CML), BCR gene fused ABL kinase
has been extensively explored as a validated target of drug discovery. Although imatinib has …
has been extensively explored as a validated target of drug discovery. Although imatinib has …
Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).
T Lu, J Cao, F Zou, X Li, A Wang, W Wang… - European Journal of …, 2021 - europepmc.org
As the critical driving force for chronic myeloid leukemia (CML), BCR gene fused ABL kinase
has been extensively explored as a validated target of drug discovery. Although imatinib has …
has been extensively explored as a validated target of drug discovery. Although imatinib has …
Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML)
T Lu, J Cao, F Zou, X Li, A Wang… - European journal …, 2021 - pubmed.ncbi.nlm.nih.gov
As the critical driving force for chronic myeloid leukemia (CML), BCR gene fused ABL kinase
has been extensively explored as a validated target of drug discovery. Although imatinib has …
has been extensively explored as a validated target of drug discovery. Although imatinib has …
Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML)
T Lu, J Cao, F Zou, X Li, A Wang, W Wang… - European Journal of …, 2021 - Elsevier
As the critical driving force for chronic myeloid leukemia (CML), BCR gene fused ABL kinase
has been extensively explored as a validated target of drug discovery. Although imatinib has …
has been extensively explored as a validated target of drug discovery. Although imatinib has …